In cardiovascular outcome trials (CVOTs) such as Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA-REG OUTCOME), CANagliflozin cardioVascular Assessment Study (CANVAS) and The Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) [6], they reduced the onset and progression of DKD, which was confirmed in the dedicated kidney trial The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), which showed a canagliflozin-induced risk reduction for ESKD in people with DKD by 32% [7]
As employers grapple with how to pay for these medications, some are exploring strategies like: Limiting coverage to patients with the highest need Pairing GLP-1 coverage with a dietician to improve nutrition, support for physical exercise and intensive behavioral health therapy Alternative payment models that hold drug manufacturers accountable for producing results GLP-1s deliver impressive clinical results but at a steep cost
These agents include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)
Wang W, Nevrez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J
